HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.
HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.